NGEN vs NMRA

NervGen Pharma Corp. vs Neumora Therapeutics, Inc. — Valuation Comparison 2026

NGEN

Biotechnology
NervGen Pharma Corp.
Quality
3.1
out of 10
Value Trap
Price
$2.08
Last close
Models
6/13
Active
VS

NMRA

Biotechnology
Neumora Therapeutics, Inc.
Quality
3.8
out of 10
Value Trap
30
LOW
Price
$1.88
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType NGEN Fair ValueNGEN Upside NMRA Fair ValueNMRA Upside
Bayesian DCF Intrinsic $0.64 -69.5% $0.82 -56.5%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $0.09 -95.6% $1.55 -17.4%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for NGEN vs NMRA — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

NGEN vs NMRA — Which Stock Is More Undervalued?

NMRA scores higher with a 3.8/10 quality rating vs NGEN's 3.1/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing NervGen Pharma Corp. (NGEN) and Neumora Therapeutics, Inc. (NMRA) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

NGEN currently trades at $2.08 with a QOC of 3.1/10, while NMRA trades at $1.88 with a QOC of 3.8/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).